

## INDUSTRY PROGRAM – INDEPENDENT SATELLITE SYMPOSIA (updated on June 07)

### TUESDAY, JUNE 13

11:30 – 13:00 Room A

Kite, A Gilead Company

#### **Improving outcomes in R/R DLBCL: Learning from challenging cases**

Chair: Marie-José Kersten, Amsterdam, NL

Every patient is different, and due to the patient demographic in DLBCL, some can have multiple health-related issues. How do we manage those more complex cases? This interactive symposium will explore the use of CAR T for complex R/R DLBCL cases based on real-world experiences. Speakers will share cases, highlighting the challenges they faced and the solutions they used, then the panel will discuss the patient management and treatment decision-making. Audience questions are encouraged to ensure a lively, discussion-led symposium that offers the opportunity to share experiences to improve outcomes for patients with R/R DLBCL treated with CAR T-cell therapy.

11:30

Introduction

Marie-José Kersten, Amsterdam, NL

11:35

Challenges in R/R DLBCL: Overview

Marie-José Kersten, Amsterdam, NL

11:45

Case study 1

Chris Fox, Nottingham, GB

All faculty (moderator: Marie-José Kersten, Amsterdam, NL)

12:00

Case study 2

Wendy Osborne, Newcastle, GB


All faculty (moderator: Marie-José Kersten, Amsterdam, NL)

12:15


Case study 3

Olalekan Oluwole, Nashville, TN, US

All faculty (moderator: Marie-José Kersten, Amsterdam, NL)



12:30		Case study 4 Miguel-Angel Perales, New York, NY, US All faculty (moderator: Marie-José Kersten, Amsterdam, NL)
12:45		Q&A All faculty (moderator: Marie-José Kersten, Amsterdam, NL)
11:30 – 13:00	Room B1	Regeneron <b>Optimizing Treatment Paradigms for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) With the Emerging Class of Bispecific Antibodies</b>
11:30		Bispecifics: Novel Mechanisms for Immunotherapies in Follicular Lymphoma and DLBCL Pier Luigi Zinzani, Bologna, IT
11:38		Disease State and Unmet Needs in Follicular Lymphoma Stefano Luminari, Reggio Emilia, IT
11:48		Expanding Treatment Options With Bispecifics in R/R FL Stefano Luminari, Reggio Emilia, IT
12:06		Panel Discussion on Follicular Lymphoma All Faculty
12:19		Disease State and Unmet Needs in Diffuse Large B-cell Lymphoma Jason Westin, MD, Houston, Texas, USA
12:27		Expanding Treatment Options With Bispecifics in DLBCL Jason Westin, MD, Houston, Texas, USA
12:45		Panel Discussion on DLBCL All Faculty



11:30 – 13:00 Room B2

Eli Lilly and Company

### **Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients**

Treatment for R/R MCL is complicated, as the disease typically presents in elderly, unfit patients; however, emerging targeted therapy options have shown great promise based on excellent results in clinical trials. In this symposium, expert faculty will present therapeutic options, established by evidence-based practice guidelines, for patients with R/R MCL. Engage with expert faculty as you 'Build Your Own Case' study live. You and your peers can vote on patient demographics and parameters such as treatment, dosing frequency, and adverse events. The experts will craft their lecture to follow your suggestions allowing the case studies to reflect the patients you see. The symposium will conclude with a discussion on engagement between healthcare providers and patients to improve clinical outcomes.

Welcome and introductions

Mats Jerkeman, Lund, SE

The evolving landscape of treatment options for R/R MCL

Mats Jerkeman, Lund, SE

Build Your Own Case Study LIVE 1

Christiane Pott, Kiehl, DE

Build Your Own Case Study LIVE 2


Carlo Visco, Verona, IT

The importance of collaboration between providers and patients

All faculty

Faculty / learner Exchange

All faculty



14:00 – 15:30 Room A

Kite, A Gilead Company

**Evolving survival outcomes with CAR T in 2L DLBCL**

Chair: Anna Sureda, Barcelona, ES

Patients with DLBCL who progress after initial therapy require effective treatment options but the last change in standard of care was nearly 30 years ago. This symposium will examine challenges and unmet medical need in 2L DLBCL. An update on the latest advances with CAR T at first relapse will be provided, looking at how this is changing the 2L treatment landscape. Our experts will discuss their clinical experience and share insights into patient selection and management. We encourage you to take the opportunity to interact with the authors of these studies to bring benefit to your patients.

14:00

Introduction

Anna Sureda, Barcelona, ES

14:05

Defining the unmet need in 2L DLBCL

Michael Dickinson, Melbourne, AU

14:15

How has CAR T changed the 2L DLBCL treatment landscape?

Frederick Locke, Tampa, FL, US and Matthew Lunning, Omaha, NE, US

14:40

CAR T in 2L DLBCL: a case study

Jason R. Westin, Houston, TX, US

14:55


Interactive patient management panel discussion and Q&A

All faculty

15:25

Close

Anna Sureda, Barcelona, ES



14:00 – 15:30 Room B1

Novartis

### Using Real-World Experience to Optimize CAR-T Cell Therapy in Lymphoma

Chair: Thorsten Zenz, Zurich, CH

Real-world experience is invaluable for informing treatment decisions and optimizing outcomes in patients with relapsed/refractory (r/r) lymphomas. In this symposium, the expert faculty will share best practices and learnings from day-to-day clinical experience for management of r/r diffuse large B-cell lymphoma and r/r follicular lymphoma using chimeric antigen receptor (CAR) T-cell therapies. Patient case-based discussions will center around optimizing patient identification, pre-infusion patient management, and current barriers to timely referral. Professors Thorsten Zenz, Ulf Schnetzke, and Roch Houot will look to the future and discuss the impact next-generation CAR-T cell therapies will have on clinical practice.

Introductions and opening remarks

Thorsten Zenz, Zurich, Switzerland

Real-world patient identification and management for CAR-T cell therapy—  
Third-line r/r DLBCL

Summary of real-world data

Thorsten Zenz, Zurich, CH

Patient identification and clinical outcomes

Thorsten Zenz, Zurich, CH


Pre-infusion patient management

Ulf Schnetzke, Jena, DE

Real-world patient identification and referral for CAR-T cell therapy—r/r FL  
Optimizing patient identification and timing of referral for CAR-T cell  
therapy

Roch Houot, Rennes, FR

Looking forward to next-generation CAR-T cell therapies—DLBCL and FL



Potential impact of next-generation CAR-T cell therapies on patient identification and clinical outcomes

Ulf Schnetzke, Jena, DE

Roch Houot, Rennes, FR

All faculty, moderated by Thorsten Zenz, Zurich, CH

Q&A live session

All faculty, moderated by Thorsten Zenz, Zurich, CH

Closing Remarks

Thorsten Zenz, Zurich, CH

14:00 – 15:30 Room B2

Incyte

**What to do when CAR Ts are not the most appropriate option in 2L DLBCL. Current treatment options for transplant-ineligible patients**

Chair: Björn Chapuy, Berlin, DE

In this innovative session, our distinguished faculty will share their valuable expertise on currently approved treatments for 2L DLBCL. How do you address treatment decisions for patients with R/R DLBCL who cannot receive ASCT or CAR T in 2L? First, we will focus on shared decision-making to examine how to recognise patient needs and preferences in treatment choices, featuring unique insights from a representative of the patient advocacy group, Lymphoma Coalition. This will be followed by a dynamic debate around the available treatments for 2L DLBCL, including patient cases and live voting on the treatments discussed.

14:00

Introduction

Björn Chapuy, Berlin, DE

14:05

Part 1: Shared decision-making: when 1L fails

Philipp Staber, Vienna, AT and Natacha Bolaños, Lymphoma Coalition, EU


14:30

Part 2: Controversy: Available treatments in 2L DLBCL today.

Clinical case discussions

Eva González Barca, Barcelona, ES

Gabriel Brisou, Marseille, FR



15:20

Conclusion  
Björn Chapuy, Berlin, DE

14:00 – 15:30 Auditorium  
West Campus USI

MSD  
**Aggressive B-cell lymphomas, ROR1 modalities and ADCs: Why it Matters**  
Chair: Thomas Kipps, La Jolla, CA, US

Please join the MSD live symposium on 13 June 2023 at 14:00 CEST. Our distinguished faculty, Thomas Kipps, Michael Wang and Pier Luigi Zinzani will discuss the role of ROR1 inhibitors in aggressive NHL, review the ROR1 treatment options in development across aggressive NHL, and discuss the most recent data on ADCs throughout the DLBCL treatment landscape. Attendees will have the opportunity to have their questions answered by the expert panel, enhancing the interactivity of this symposium.

14:00

Welcome and Introduction  
Thomas Kipps, La Jolla, CA, US

14:10

ROR1 as a Target in aNHL  
Thomas Kipps, La Jolla, CA, US

14:30

ROR1 Modalities in aNHL  
Michael Wang, Houston, TX, US

14:50


ADCs in DLBCL: Current & Future  
Pier Luigi Zinzani, Bologna, IT

15:10

Panel Discussion and Q & A  
All faculty

15:25

Closing Remarks  
Thomas Kipps, La Jolla, CA, US



16:30 – 18:00 Room A

Bristol Myers Squibb

**Advances in the Management of B Cell Malignancies: Updates and Future Directions**

Chair: Jeremy Abramson, Boston, MA, US

Dr Jeremy Abramson, chair and speaker, will start this 90-minute symposium by presenting the key aspects of the recent developments in CAR T cell therapy for the management of LBCL patients. Dr Francesc Bosch will then provide an overview of the latest clinical efficacy and safety data regarding the existing CAR T cell therapies in CLL, followed by Dr Emmanuel Bachy who will discuss current and emerging approaches in the treatment of non-Hodgkin lymphoma. Finally, attendees will have the opportunity to ask questions to the panel of experts.

16:30

Welcome and introduction

Jeremy Abramson, Boston, MA, US

16:35

Advancing CAR T cell therapies in LBCL

Jeremy Abramson, Boston, MA, US

16:55

CAR T cell therapy in CLL: latest data and perspectives

Francesc Bosch, Barcelona, ES

17:20

Novel approaches for immunomodulatory treatment of NHL

Emmanuel Bachy, Lyon, FR

17:45

Q&A and discussion

All faculty, moderated by Jeremy Abramson

Closing remarks

16:30 – 18:00 Room B1


Genmab

**Beyond the Horizon: Perspectives on the Treatment of Later-Line Large B-Cell Lymphoma (LBCL)**

Chair: Chan Cheah, Perth, AU

The treatment landscape for relapsed/refractory large B-cell lymphoma (LBCL) has changed dramatically in the last few years. In this symposium,





Professors Pau Abrisqueta, Chan Cheah, and Martin Hutchings will discuss the current landscape and efficacy and safety of novel treatments for later-line LBCL and how these will impact the treatment of patients in the coming years.

Relapsed/refractory LBCL: Exploring chemo-free treatment alternatives  
Pau Abrisqueta, Barcelona, ES

Epcoritamab monotherapy for third-line or later LBCL  
Chan Cheah, Perth, AU

Advances in response assessments for LBCL and other lymphomas  
Martin Hutchings, Copenhagen, DK

16:30 – 18:00 Room B2

Roche

**T-cell engaging bispecific antibodies in the management of relapsed/refractory follicular lymphoma**


Chair: Graham Collins, Oxford, GB

This satellite symposium at ICML 2023 will offer the opportunity to learn from experts about the use of T-cell engaging bispecific antibodies in the management of relapsed/refractory follicular lymphoma (FL). Efficacy and safety of emerging bispecific antibodies including mosunetuzumab, epcoritamab, odronextamab and glofitamab will be reviewed, as will the management of common side effects, such as CRS. The prognostic value of PET and its role in response-adapted therapy will be presented and discussed. The impact of emerging T-cell engaging therapies on the FL treatment landscape will be explored along with factors influencing their use and adoption in clinical practice.

16:30 Introduction and welcome  
Graham Collins, Oxford, GB

16:35 New treatment options in R/R FL  
Kai Hübel, Cologne, DE

16:55 Clinical guidance on the use of bispecific antibodies in R/R FL



Matthew Matasar, New Jersey, NJ, US

17:15

Assessing treatment efficacy in FL  
Judith Trotman, Sydney, NSW, AU

17:35

The future of bispecific antibodies in the evolving treatment landscape  
Graham Collins, Oxford, GB

17:45

Panel discussion and Q&A  
All faculty

16:30 – 18:00 Auditorium  
West Campus USI

Satellite symposium organized by PeerView, supported by AstraZeneca  
**Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies**  
Chair: Martin Dreyling, Munich, DE

In this MasterClass & Case Forum event, our panel of experts will use a blended lecture and case-based approach to provide learners with insight on the latest clinical evidence supporting novel therapeutics, including BTKi, bispecific antibodies, and cellular therapy in MCL treatment. Each session will provide guidance on the differences between covalent BTKi options that can inform treatment selection and utilization strategies for novel therapeutic options across the spectrum of MCL care. Adapt your practice to reflect the growing role of targeted agents within a multipronged treatment model for MCL, and improve patient outcomes—register today!


For further information, please visit:  
[PeerView.com/Lugano23](https://www.peerview.com/Lugano23)

16:30


Welcome & MasterClass Prep: Laying the Foundation for Better MCL Care  
Martin Dreyling, Munich, DE

16:35

MasterClass: Sifting Through the Evidence With BTKi and Other Innovative Strategies  
Toby A. Eyre, Oxford, GB and Kami Maddocks, Columbus, OH, US



16:40		Case Forum: Seizing Opportunities to Challenge Conventional Care Martin Dreyling, Munich, DE, Toby A. Eyre, Oxford, GB and Kami Maddocks, Columbus, OH, US
16:45		Symposium Summary and Audience Q&A
18:00		Adjourn
19:00 – 20:30	Room A	Roche <b>What does the future hold for DLBCL treatment and prognosis?</b> Chair: Franck Morschhauser, Lille, FR  Our understanding of DLBCL disease biology continues to evolve, and with this comes the possibility of improving patient outcomes with a precision-based approach. In this symposium, an esteemed expert faculty will discuss the latest advances in DLBCL treatment and prognosis, focusing on molecular insights into the disease. The panel will examine the relative contributions of all-comer and molecularly informed studies, and what the future of clinical trials in DLBCL may look like. This session will include a panel discussion, as well as a live and interactive Q&A in which you will have the opportunity to ask the faculty your questions.
19:00		Treating DLBCL: Where are we now? Franck Morschhauser, Lille, FR
19:05		New molecular insights into DLBCL disease and prognosis Björn Chapuy, Berlin, DE
19:30		A new era for clinical trials in DLBCL? Andrew Davies, Southampton, GB and Anna Sureda, Barcelona, ES
20:10		Experts in conversation: Future perspectives in DLBCL All faculty: live and interactive Q&A
19:00 – 20:30	Room B1	Sobi <b>Closing the gap: Unmet Needs and Emerging Treatments in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)</b>



Chair: Georg Lenz, Münster, DE

Despite advances in diffuse large B-cell lymphoma (DLBCL) therapies, a significant number of patients still experience relapsed or refractory (R/R) disease. CAR T-cell therapy may be a curative option for some patients, but a significant proportion don't receive CAR T-cell therapy or will subsequently relapse. In this symposium, Prof. Pier Luigi Zinzani will discuss challenges in treating patients with R/R DLBCL, Prof. Georg Lenz will present emerging data on antibody-drug conjugates, and Prof. Mehdi Hamadani will discuss practical insights on managing 3L patients with R/R DLBCL sharing clinical cases. Attendees will have the opportunity to engage with the speakers.

19:00  
Welcome and Introduction  
Georg Lenz, Münster, DE

19:10  
Challenges in the Current Treatment of RR DLBCL  
Pier Luigi Zinzani, Bologna, IT

19:20  
Future Advances in Later Lines of DLBCL Therapy: Can Antibody Drug Conjugates be a Solution?  
Georg Lenz, Münster, DE


19:30  
Third Line Management of R/R DLBCL and Sequencing CD19 Therapies: Real-world Experience From the US  
Mehdi Hamadani, Milwaukee, WI, US

19:40  
Ask the Experts Q&A  
All faculty

19:50  
Closing Remarks  
Georg Lenz, Münster, DE


19:00 – 20:30 Room B2

AbbVie  
**Optimizing Treatment Strategies for Patients with Chronic Lymphocytic Leukemia (CLL): An Expert Discussion**  
Chair: Thorsten Zenz, Zurich, CH



Over the past decade, advancements in chronic lymphocytic leukemia (CLL) therapeutics have led to an evolution in diagnosis and treatment considerations from a clinical perspective. With the increasing number of treatment options with unique clinical profiles, the patient perspective and their involvement in treatment decision making in CLL has never been more significant. Please join us as Professor Thorsten Zenz chairs a structured roundtable discussion with Dr. Carol Moreno and Dr. Othman Al-Sawaf to consider Optimizing Treatment Strategies for Patients with CLL.

- |       |  |
|-------|--|
| 19:00 | Introduction: Evolving Concepts in Chronic Lymphocytic Leukemia (CLL)<br>Thorsten Zenz, Zurich, CH                                       |
| 19:05 | Decisions at Diagnosis: Incorporating Disease Factors and Patient Perspectives<br>Thorsten Zenz, Zurich, CH                              |
| 19:20 | Panel Discussion<br>Thorsten Zenz, Zurich, CH  |
| 19:30 | Treatment Strategies in First-Line CLL: Continuous Duration Therapies<br>Carol Moreno, Barcelona, ES                                     |
| 19:45 | Treatment Strategies in First-Line CLL: Fixed Treatment Duration Therapies<br>Othman Al-Sawaf, Cologne, DE                               |
| 20:00 | Panel Discussion<br>Thorsten Zenz, Zurich, CH  |
| 20:10 | Roundtable Discussion: Optimizing Treatment for Patients with Relapsed/Refractory CLL & Future Perspectives<br>Thorsten Zenz, Zurich, CH |
| 20:25 | Closing<br>Thorsten Zenz, Zurich, CH   |



## WEDNESDAY, JUNE 14

19:00 – 20:30 Room A

AbbVie

### **Navigating the Rapidly Changing Treatment Landscape in DLBCL**

Chair: Georg Lenz, Münster, DE

Historically there have been limited changes in the treatment landscape for DLBCL. However, recent data are challenging the standard care in first-line as well as expanding the available options in second- and third-line. The complexity of the treatment landscape has evolved with regard to treatment sequencing and patient selection due to the advent of targeted therapies. Professor Georg Lenz will chair a structured roundtable discussion with Professors Chris Fox, Jeremy Abramson and Catherine Thieblemont to consider how to navigate the rapidly changing treatment landscape in DLBCL.

19:00

Welcome and Introduction

Georg Lenz, Münster, DE

19:05

Challenging the Standard of Care in First-Line

Chris Fox, Nottingham, GB

19:25

Selecting an Optimal Second-Line Treatment Strategy in an Evolving Landscape

Jeremy Abramson, Boston, MA, US

19:55

Navigating the Complexities of Third-Line Treatment

Catherine Thieblemont, Paris, FR

20:25

Closing


Georg Lenz, Münster, DE

19:00 – 20:30 Room B

Takeda

### **The future of therapy for CD30+ lymphomas: addressing challenges and driving progress**

Chair: Anna Sureda, Barcelona, ES




Recent advances in frontline treatment for advanced (stage III/IV) Hodgkin lymphoma have resulted in many patients achieving curative responses, but incorporation of targeted therapies and innovative strategies may further improve patient outcomes. Our expert faculty will discuss the future of therapy for CD30+ lymphomas, specifically advanced (stage III/IV) Hodgkin lymphoma and peripheral T-cell lymphoma (PTCL). Novel biomarkers for determining a patient's prognosis and likelihood of response to treatment will also be reviewed, focusing on their importance in selecting appropriate therapy for advanced Hodgkin lymphoma. In PTCL, ongoing research is expanding our understanding of effective treatment strategies, and we will explore recent advances and potential future directions in this area. The symposium aims to provide valuable insights that may help inform a tailored approach to patient care.

For further information, please visit

<https://cloud.takeda-eucan.com/eucan-onc-icm-lp>

19:00	Welcome and Introduction Anna Sureda, Barcelona, ES
19:05	Successes, challenges, and future directions in frontline advanced Hodgkin lymphoma Anna Sureda, Barcelona, ES
19:30	Emerging biomarkers of risk/response in the treatment of advanced Hodgkin lymphoma Sven Borchmann, Cologne, DE
19:55	Progress in peripheral T-cell lymphoma and current frontline management approaches Tim Illidge, Manchester, GB
20:20	Q&A All faculty
20:25	Closing remarks Anna Sureda, Barcelona, ES



19:00 – 20:30 Auditorium BeiGene  
West Campus USI **Targeting BTK across B-Cell Malignancies – Selecting the right treatment for patients with lymphoma or CLL**  
Chair: Stephen Stilgenbauer, Ulm, DE

This symposium, chaired by Professor Stephan Stilgenbauer, will discuss current and emerging BTKi-based treatments for B-cell malignancies with a particular focus on chronic lymphocytic lymphoma (CLL) and follicular lymphoma (FL). Professor Stilgenbauer will present the treatment landscape for CLL patients – the concepts of continued versus fixed duration treatment, switching from first to next generation BTKi, and how genetic subtypes influence the treatment selection will be discussed. Professor Zinzani will present the status and current treatment status in FL including emerging data from the randomized Phase 2 ROSEWOOD trial in patients with relapsed or refractory FL (zanubrutinib in combination with obinutuzumab vs. obinutuzumab monotherapy). Professor Stilgenbauer will then lead the panel discussion with the full faculty to discuss the key criteria, supported by additional patient cases, for selecting a BTKi versus other treatment options for CLL, FL, MZL and WM, especially for difficult-to-treat patients

19:00 Welcome & introduction  
Stephan Stilgenbauer, Ulm, DE


19:05 CLL: Contemporary Treatment of CLL – Selection of best treatment for your patient  
Stephan Stilgenbauer, Ulm, DE

19:15 FL: Future Direction in Management of r/r FL patients  
Pier Luigi Zinzani, Bologna, IT

19:30 Panel discussion about key criteria for selecting BTKi for CLL and lymphoma  
All faculty

19:50 Audience Q&A





All faculty

20:15

Wrap-up  
Stephan Stilgenbauer, Ulm, DE

## THURSDAY, JUNE 15

19:00 – 20:30 Room A

Kite, A Gilead Company  
**How do we improve outcomes for underserved populations with B-cell malignancies?**  
Chair: Davide Rossi, Bellinzona, CH

Clinical trial populations should be diverse in order to ensure that the full range of biological variabilities are represented. However, trial populations do not always adequately represent the full range of patients seen in clinic. This is due, in part, to the need to create homogeneous populations for controlled trials. In this non-promotional, interactive symposium, speakers will discuss the management of populations with B-cell malignancies with unmet needs, how to increase diversity and inclusion in clinical studies and how we can improve outcomes for such populations in the future and ensure equitable treatment access for all.

19:00

Introduction  
Davide Rossi, Bellinzona, CH

19:05

Are we ensuring diversity and inclusion in clinical studies?  
Mark Bishton, Nottingham, GB

19:15


Q&A  
All faculty

19:25

Are we addressing the unmet needs for all B-cell lymphomas?  
Kate Cwynarski, London, GB and Barbara F. Eichhorst, Cologne, DE

19:45

Q&A  
All faculty



19:55 Roundtable discussion: How do we improve outcomes for the underserved populations with B-cell lymphoma?  
Davide Rossi, Bellinzona, CH

20:05 Q&A  
All faculty

20:25 Close  
Davide Rossi, Bellinzona, CH

19:00 – 20:30 Room B

Janssen  
**Optimizing treatment for patients with CLL and MCL now and in the future**  
Chair: John Gribben, London, GB

Following advances in recent years there are now a number of highly efficacious and tolerable therapeutic approaches available for patients with CLL or MCL. In this symposium the faculty will evaluate how data updates are impacting the clinical management of patients with CLL and MCL, they will discuss results from recent studies that challenge the current standards of care and they will highlight the potential of new treatment options to further improve outcomes in patients with CLL and MCL.

For further information, please visit:


<https://www.janssencongress.com/emails/icml-2023-01/>

19:00 Introduction  
John Gribben, London, GB

19:05 Fixed duration or MRD-guided therapy: what's the latest data in CLL?  
Carol Moreno, Barcelona, ES

19:25 Panel discussion  
All faculty, moderated by John Gribben, London, GB

19:45 How BTK inhibitors are changing the treatment algorithm for patients with MCL  
Martin Dreyling, Munich, DE



20:05

Panel discussion

All faculty, moderated by John Gribben, London, GB

20:25

Summary and closing remarks

John Gribben, London, GB

19:00 – 20:30

Auditorium

West Campus USI

Follicular Lymphoma Foundation

**What will it take to cure Follicular Lymphoma?**

Chair: Mitchell Smith, CMO at the FLF

Supported by an independent educational grant from AstraZeneca.  
Sponsorship support from BeiGene, Novartis, and BioInvent International AB.

The progress in the last 20-30 years within basic science, technology and therapeutics means we are inching ever closer to turning what once was considered science fiction into science fact. For Follicular Lymphoma (FL) patients, the new age of cellular therapy (CAR-T, bispecific antibodies) along with the technological advances and deeper understanding of the underlying complex biological mechanisms (MRD, clonal dynamics), means that we now have a unique opportunity to change the existing paradigm – to cure FL.

Join us at the FLF symposium where Dr Mitchell Smith along with the expert faculty will review recent advances in Follicular Lymphoma (FL) therapy and pathophysiology, before opening an engaging discussion on how we can leverage these key advances to develop and assess future curative approaches for FL patients.

19:00

T-cell engaging therapies – CAR-T and bispecific antibodies in FL:

Is there evidence of curing subsets of FL patients?


Loretta J. Nastoupil, Houston, TX, US

19:15

The biology of Common Precursor Cells (CPCs) and approaches to eradicating them:

What are the therapeutic barriers to reaching a cure in FL?

Jessica Okosun, London, GB



- 19:30 Minimal Residual Disease (MRD) assays – today and tomorrow:  
How can we show FL patients are cured, without waiting a lifetime?  
Marco Ladetto, Turin, IT
- 19:45 The role of epigenetic mutations – in FL, resistance, and as treatment  
targets:  
How can we optimally use epigenetic and other targeted approaches?  
Ari M. Melnick, New York, NY, US
- 20:00 Full panel discussion: Laying the pathway to cure